Latest news with #ALPMY
Yahoo
27-05-2025
- Business
- Yahoo
Is Astellas Pharma (ALPMY) Stock Outpacing Its Medical Peers This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Astellas Pharma Inc. (ALPMY) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question. Astellas Pharma Inc. is a member of the Medical sector. This group includes 997 individual stocks and currently holds a Zacks Sector Rank of #4. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Astellas Pharma Inc. is currently sporting a Zacks Rank of #1 (Strong Buy). Over the past 90 days, the Zacks Consensus Estimate for ALPMY's full-year earnings has moved 20.7% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving. Our latest available data shows that ALPMY has returned about 0.3% since the start of the calendar year. At the same time, Medical stocks have lost an average of 7.1%. As we can see, Astellas Pharma Inc. is performing better than its sector in the calendar year. Another stock in the Medical sector, AtriCure (ATRC), has outperformed the sector so far this year. The stock's year-to-date return is 7%. For AtriCure, the consensus EPS estimate for the current year has increased 25.1% over the past three months. The stock currently has a Zacks Rank #2 (Buy). Breaking things down more, Astellas Pharma Inc. is a member of the Medical - Drugs industry, which includes 161 individual companies and currently sits at #52 in the Zacks Industry Rank. On average, this group has lost an average of 2% so far this year, meaning that ALPMY is performing better in terms of year-to-date returns. In contrast, AtriCure falls under the Medical - Products industry. Currently, this industry has 82 stocks and is ranked #147. Since the beginning of the year, the industry has moved +3.8%. Investors interested in the Medical sector may want to keep a close eye on Astellas Pharma Inc. and AtriCure as they attempt to continue their solid performance. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Astellas Pharma Inc. (ALPMY) : Free Stock Analysis Report AtriCure, Inc. (ATRC) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
23-05-2025
- Business
- Business Insider
Astellas Pharma and Pfizer's Xtandi shows long-term survival in prostate cancer
Astellas Pharma (ALPMY) and Pfizer (PFE) announced longer-term follow-up results from an open-label extension of the Phase 3 ARCHES study, reporting a five-year follow up of overall survival, or OS, benefits and a 30% reduction in the risk of death in men with metastatic hormone-sensitive prostate cancer treated with Xtandi – enzalutamide -, an androgen receptor pathway inhibitor, plus androgen deprivation therapy vs. placebo plus ADT. These data will be presented at the American Society of Clinical Oncology Annual Meeting in Chicago. In patients with high-volume disease a 36-month improvement in median OS was observed. Additional clinically relevant subgroups of patients were evaluated, showing consistently improved survival: low-volume disease; patients who had previously received docetaxel therapy and those who had not received prior docetaxel therapy. The incidence of treatment-emergent adverse events in the five-year follow-up is consistent with prior ARCHES analyses and no new safety signals were identified. These results of the five-year follow-up from the ARCHES study will be submitted for publication in a peer-reviewed journal in the near future. The median OS in the XTANDI group was 8.0 years and 5.8 years in the NSAA group. OS at 96 months was 50% with Xtandi and 40% for NSAA; progression-free survival also favored Xtandi over NSAA. Mean duration of treatment was longer for Xtandi than NSAA, with 33% remaining on Xtandi and 88% of these patients remained at the full dose of 160 mg. Confident Investing Starts Here:
